| abstract |
The invention relates to simple variable domains (dAb) of anti-TNFR1 polypeptides and antibodies that are resistant to degradation by a protease, as well as to the antagonists comprising these. The polypeptides, dAb and antagonists are useful as therapeutic and / or prophylactic probably to combat proteases when administered to a patient, for example by pulmonary administration, oral administration, lung delivery and supply to a patient's GI tract, as well as for treat inflammatory diseases, such as arthritis or COPD (COPD). 1. A simple variable domain of the anti-TNFa type 1 receptor immunoglobulin (TNFR1; p55) comprising an amino acid sequence that is at least 93% identical to the amino acid sequence of DOM1h-131-206 (shown in Figure 3) .2.- The simple variable domain of the immunoglobulin of claim 1 comprising aspartic acid at position 53, wherein the numbering is according to Kabat. 3. The simple variable domain of the immunoglobulin of claim 1 or 2 comprising histidine at position 91, where the numbering is according to Kabat. 4.- A simple variable domain of the anti-TNFa type 1 receptor immunoglobulin (TNFR1; p55) comprising an amino acid sequence that is identical to the amino acid sequence of DOM1h-131-206 (as shown in the figure 3). 5.- A simple variable domain of the anti-TNFa type 1 receptor immunoglobulin (TNFR1; p55) encoded by a nucleotide sequence that is at least 80% identical to the nucleotide sequence of DOM1h-131-206 (shown in Figure 19). 6.- A simple variable domain of the anti-TNFa type 1 receptor immunoglobulin (TNFR1; p55) encoded by a sequence that is identical to the nucleotide sequence of DOM1h-131-206 (shown in Figure 19). |